Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024
06 mars 2024 01h30 HE
|
Transgene S.A.
Poster presentation of new data from ongoing randomized Phase I trial targeting head and neck cancers Strasbourg, France, March 6, 2024, 7:30 a.m. CET – Transgene (Euronext Paris: TNG), a...
Transgene, NEC et BostonGene étendent leur collaboration dans le cadre de l’essai clinique de Phase I/II du vaccin individualisé TG4050
05 mars 2024 01h30 HE
|
Transgene S.A.
Strasbourg (France), Tokyo (Japon), Waltham (Mass. USA) – le 5 mars 2024, 7h30 - Transgene (Euronext Paris : TNG), une société de biotechnologie qui conçoit et développe des immunothérapies du cancer...
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
05 mars 2024 01h30 HE
|
Transgene S.A.
Strasbourg (France), Tokyo (Japan) and Waltham, Mass (USA), March 5th, 2024, 7:30 am CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for...
Transgene annonce la nomination de James Wentworth comme Directeur du Business Development
22 janv. 2024 11h45 HE
|
Transgene S.A.
Strasbourg, France – Le 22 janvier 2023, 17 h 45 – Transgene (Euronext Paris : TNG), société de biotechnologie qui conçoit et développe des immunothérapies contre le cancer reposant sur des vecteurs...
Transgene Further Strengthens Management Team with Appointment of James Wentworth as Chief Business Officer
22 janv. 2024 11h45 HE
|
Transgene S.A.
Strasbourg, France, January 22, 2024, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, is pleased...
Transgene présente son calendrier de communication financière pour 2024
22 janv. 2024 02h00 HE
|
Transgene S.A.
Strasbourg, le 22 janvier 2024, 08h00 TRANSGENE (Paris : TNG) communique aujourd’hui son calendrier de communication financière pour 2024 : 27 mars 2024 : Résultats annuels...
Transgene Announces Financial Calendar for 2024
22 janv. 2024 02h00 HE
|
Transgene S.A.
Strasbourg (France), January 22, 2024 - 08:00 am CET TRANSGENE (Paris: TNG) today announced its financial reporting dates for 2024. March 27, 2024: 2023 Fiscal Year Results May 14,...
Transgene et NEC étendent leur collaboration et poursuivent ensemble le développement clinique de TG4050, un vaccin thérapeutique individualisé contre le cancer
08 janv. 2024 11h45 HE
|
Transgene S.A.
Transgene et NEC prévoient de lancer, en 2024, une extension de l’étude randomisée de Phase I en essai randomisé de phase I/II pour continuer à démontrer le potentiel de TG4050 comme traitement...
Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050
08 janv. 2024 11h45 HE
|
Transgene S.A.
Transgene and NEC plan to start an extension of the randomized Phase I trial into a randomized Phase I/II study in 2024 to further demonstrate the potential of TG4050 as an adjuvant treatment of...
Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of December 31, 2023
04 janv. 2024 11h45 HE
|
Transgene S.A.
Strasbourg, January 4, 2024 – 05:45 pm CET Under the liquidity contract entrusted by Transgene to Natixis Oddo BHF SCA, as of December 31, 2023, the following resources were managed through the...